Variability and quantification of serum medroxyprogesterone acetate levels.

Area of Science:

• Pharmacology
• Analytical Chemistry
• Reproductive Health

Background:

• Serum progestin quantification is vital in contraceptive studies for pharmacokinetic analysis and to verify self-reported usage.
• Depot medroxyprogesterone acetate intramuscular injection (DMPA-IM) is a common three-monthly progestin-only contraceptive.
• Existing quantification methods like LC/MS and RIA have variations in protocols and standardization.

Purpose of the Study:

• To review and highlight the variability in current methods for quantifying serum medroxyprogesterone acetate (MPA).
• To identify the need for standardization in MPA quantification and sampling times for clinical studies.
• To improve the interpretation of clinical data and side effects related to DMPA-IM pharmacokinetics.

Main Methods:

• Literature review of serum MPA quantification methods, including liquid chromatography coupled to mass spectrometry (LC/MS) and radioimmunoassay (RIA).
• Analysis of variations in LC/MS methodology, such as organic solvent extraction, derivatization, and chromatography.
• Examination of potential overestimation of progestin levels by RIA without organic solvent extraction.

Main Results:

• Significant variations exist in LC/MS methodology, with a lack of standardized extraction protocols.
• Limited evidence suggests RIA may overestimate progestin levels when organic solvent extraction is omitted.
• Wide inter-individual and inter-study variations in maximum MPA concentrations are observed within the first two weeks post-injection, irrespective of the quantification method.

Conclusions:

• Standardization of MPA quantification methods and post-injection sampling times is essential for accurate interpretation of clinical contraceptive study data.
• Improved standardization will aid in understanding the pharmacokinetic profile of injectable contraceptives and their associated side effects.
• Addressing methodological variations is key to advancing research on DMPA-IM and other progestin-only contraceptives.